NASDAQ · OKYO
OKYO Pharma Limited financials
$1.36−0.73%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Mar 31 | FY25 Mar 31 | FY24 Mar 31 | FY23 Mar 31 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$8.5M | -$7.1M | -$15.7M | -$13.2M |
| Net income | -$8.9M | -$4.7M | -$16.8M | -$13.3M |
| Net margin | — | — | — | — |
| Diluted EPS | $-0.24 | $-0.12 | $-0.57 | $-0.61 |
| EBITDA | -$8.5M | -$7.1M | -$15.7M | -$13.2M |
| Operating cash flow | -$5.9M | -$1.8M | -$9.5M | -$7.7M |
| Free cash flow | -$5.9M | -$1.8M | -$9.5M | -$7.7M |
| Diluted shares | 37.4M | 39.5M | 29.3M | 22.3M |
Balance sheet
| Period end | Mar 31 | Mar 31 | Mar 31 | Mar 31 |
|---|---|---|---|---|
| Cash & equivalents | $14.6M | $1.6M | $826.8K | $4.0M |
| Short-term investments | $6.0M | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $21.0M | $3.7M | $1.5M | $5.2M |
| Total liabilities | $8.6M | $9.2M | $7.4M | $7.3M |
| Shareholders' equity | $12.3M | -$5.5M | -$5.9M | -$2.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology